GlassScriptPhysician profile
Brett D Robbins
NPI 1295843449
$7,694.82
in general payments reported to CMS, 2019-2025
36 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $576 · 2021: $54.11 · 2022: $911 · 2023: $1,547 · 2024: $1,821 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,946.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,492.96 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $878.11 | 2019-2025 | |
| Tris Pharma INC | $673.49 | 2022-2025 | Dyanavel Xr |
| Novo Nordisk INC | $630.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $540.52 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.58 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $451.01 | 2019-2025 | Evenity, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $320.25 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $305.83 | 2019-2025 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $260.88 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Teva Pharmaceuticals USA, INC. | $187.10 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.97 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $151.04 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $137.11 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.85 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $88.47 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $83.80 | 2024-2025 | Voquezna |
| Abbott Laboratories | $83.14 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $82.79 | 2022 | |
| Exact Sciences Corporation | $78.41 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $76.70 | 2019-2025 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $61.95 | 2019-2020 | |
| Allergan, INC. | $48.14 | 2020 | |
| Shire North American Group INC | $42.95 | 2019 | |
| Amarin Pharma, INC. | $41.70 | 2019-2020 | |
| Dynavax Technologies Corporation | $36.43 | 2022-2024 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $30.57 | 2022-2023 | Quviviq |
| Scpharmaceuticals INC. | $20.21 | 2025 | |
| Medtronic, INC. | $18.51 | 2024 | Intellis Adaptivestim |
| Astellas Pharma US INC | $17.54 | 2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $15.60 | 2021 | |
| Shionogi INC | $15.33 | 2019 | |
| Stryker Corporation | $15.15 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amneal Pharmaceuticals LLC | $14.78 | 2023 | Unithroid |
| Inspire Medical Systems, INC. | $13.35 | 2024 | Inspire |
| Ibsa Pharma INC. | $12.70 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.